1. Diagnosis and treatment of non-muscle invasive bladder cancer;Chang;Am Urol Assoc (AUA) Guideline,2016
2. European Association of Urology Guidelines on non–muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ);Babjuk;Eur Urol,2022
3. Maintenance bacillus calmette-guerin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study;Lamm;J Urol,2000
4. US Food and Drug Administration. BCG-unresponsive non-muscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for Industry. Available at: https://www.fda.gov/media/101468/download. (Last accessed July 2020) (2018).
5. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group;Kamat;J Clin Oncol,2016